2022
Breadcrumbs:  homepage  Publications  2022

227. Y.F. Xia, J.N. An, J.Y. Li, W.X. Gu, Y.F. Zhang, S.S. Zhao, C.Z. Zhao, Y. Xu, B. Li, Z.Y. Zhong*, F.H. Meng*, Transferrin-guided intelligent nanovesicles augment the targetability and potency of clinical PLK1 inhibitor to acute myeloid leukemia, Bioactive Mater. 2023, 21, 499-510.227.pdf

226. J. Sun, Z.Y. Huangfu, J.T. Yang, G.L. Wang*, K. Hu*, M.Y. Gao, Z.Y. Zhong*, Imaging-Guided Targeted Radionuclide Tumor Therapy: From Concept to Clinical Translation, Adv. Drug Deliv. Rev. 2022, 190, 114538.226.pdf

225. X.Y.Ji*, Z.Y. Zhong*, External stimuli-responsive gasotransmitter prodrugs: Chemistry and spatiotemporal release, J. Control. Release 2022, 351, 81-101.225.pdf

224. J.J. Jiang, R.X. Wang, L. Yang, Y.J. Sha, S.S. Zhao, D.F. Chen*, Z.Y. Zhong*, F.H. Meng*, IL-11Rα-targeted nanostrategy empowers chemotherapy of relapsed and patient-derived osteosarcoma, J. Control. Release 2022, 350, 460-470.224.pdf

223. Z. Wang, B.B. Guo, S.J. Yue, S.S. Zhao, F.H. Meng*, Z.Y. Zhong*, HER-2-mediated nano-delivery of molecular targeted drug potently suppresses orthotopic epithelial ovarian cancer and metastasis, Int. J. Pharm. 2022, 625, 122126.223.pdf

222. J.Y. Liu, L. Zhang, D.X. Zhao, S.J. Yue, H.L. Sun*, C.F. Ni*, Z.Y. Zhong*, Polymersome-stabilized doxorubicin-lipiodol emulsions for high-efficacy chemoembolization therapy, J. Control. Release 2022, 350, 122-131.222.pdf

221. Q. Zhang, Y.Y. Liu, Y.C. Fei, J.G. Xie, X.F. Zhao, Z.Y. Zhong*, C. Deng*, Phenylboronic Acid-Functionalized Copolypeptides: Facile Synthesis and Responsive Dual Anticancer Drug Release, Biomacromolecules 2022, 23, 2989-2998.221.pdf

220. Y. Zheng*, Z.Y. Zhong*, Roadmap to next-generation cancer vaccines, J. Control. Release 2022, 347, 308-313.220.pdf

219. J.J. Wei, D. Wu, Y. Shao, B.B. Guo, J.J. Jiang, J. Chen, J.P. Zhang, F.H. Meng*, Z.Y. Zhong*, ApoE-mediated systemic nanodelivery of granzyme B and CpG for enhanced glioma immunotherapy, J. Control. Release 2022, 347, 68-77.219.pdf

218. B.B. Guo, J.J. Wei, J.Y. Wang, Y.P. Sun, J.D. Yuan, and Z.Y. Zhong*, F.H. Meng*, CD44-targeting hydrophobic phosphorylated gemcitabine prodrug nanotherapeutics augment lung cancer therapy, Acta Biomaterialia 2022, 145, 200-209.218.pdf

217. H. Zheng, B.B. Guo, X.Y. Qiu, Y.F. Xia, Y. Qu, L. Cheng*, F.H. Meng*, Z.Y. Zhong*, Polymersome-Mediated Cytosolic Delivery of Cyclic Dinucleotide STING Agonist Enhances Tumor Immunotherapy, Bioactive Mater. 2022, 16, 1-11.217.pdf

216. J.J. Wei, D. Wu, S.S. Zhao, Y. Shao, Y.F. Xia, F.H. Meng*, D.W. Ni, X.Y. Qiu, J.P. Zhang, J. Chen*, and Z.Y. Zhong*, Immunotherapy of Malignant Glioma by Non-Invasive Administration of TLR9 Agonist CpG Nano-immunoadjuvant, Adv. Sci. 2022, 202103689.216.pdf

215.H.H. Fang, Y.J. Sha, L. Yang, J.J. Jiang, L.C. Yin, J.Y. Li, B. Li, B. Klumperman, Z.Y. Zhong*, and F.H. Meng*, Macrophage-Targeted Hydroxychloroquine Nanotherapeutics for Rheumatoid Arthritis Therapy, ACS Appl. Mater. Interfaces 2022, 14, 8824-8837.215.pdf

214.S.J. Yue, Y.F. Zhang, Y.H. Wei, R. Haag, H.L. Sun*, and Z.Y. Zhong*, Cetuximab-Polymersome-Mertansine Nanodrug for Potent and Targeted Therapy of EGFR-Positive Cancers, Biomacromolecules 2022, 23, 100-111.214.pdf

213.Y.F. Zhang, J.N. An, Y. Shao, N. Yu, S.J. Yue, H.L. Sun*, J.B. Zhang, W.X. Gu, Y.F. Xia, J.P. Zhang, Y. Xu*, and Z.Y. Zhong*, CD38-Directed Vincristine Nanotherapy for Acute Lymphoblastic Leukemia, Biomacromolecules 2022, 23, 377-387.213.pdf

212.Z. Wang, S.S. Zhao, F.H. Meng*, J.D. Yuan, and Z.Y. Zhong*, Folate-mediated targeted PLK1 inhibition therapy for ovarian cancer: A comparative study of molecular inhibitors and siRNA therapeutics, Acta Biomaterialia 2022, 138, 443-452.212.pdf

211.X.Y.Qiu, Y.Qu, B.B.Guo, H.Zheng, F.H. Meng*, and Z.Y. Zhong*, Micellar paclitaxel boosts ICD and chemo-immunotherapy of metastatic triple negative breast cancer, J. Control. Release 2022, 341, 498-510.211.pdf